There are currently 315 clinical trials in Fort Worth, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Cook Children's Medical Center, GSK Investigational Site, Cook Children's Medical Center - Fort Worth and UT Southwestern/Simmons Cancer Center-Fort Worth. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Baylor Scott & White -Dallas, Fort Worth, Texas
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Register for Updates
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559
Recruiting
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for pur... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Cook Children's Hospital-Hematology-Oncology, Fort Worth, Texas
Conditions: Haemophilia A and B With and Without Inhibitors
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Social Experiences and Demographic Factors in the Regulation of Immune Cells
NCT06519487
Recruiting
Immune-mediated inflammatory diseases are a health burden for approximately seven percent of the population of Western nations. Preliminary data suggest variations in ethnic identity and/or geography influence discrimination experiences and inflammatory response trends. This study investigates how geography, ethnicity, and laboratory manipulation of discrimination experiences affect immune cell function and genomic regulation. Flow cytometry and immune cell stimulation will test monocytes collec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Texas Christian University, Fort Worth, Texas
Conditions: Perceived Discrimination, RNA, Inflammatory Response
Register for Updates
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: GI Alliance Research Fort Worth, Fort Worth, Texas
Conditions: Crohn's Disease
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Cook Children's, Fort Worth, Texas
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
NCT06450041
Recruiting
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
01/30/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Neuroblastoma
Register for Updates
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children with SCN1A-Positive Dravet Syndrome
NCT05419492
Recruiting
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.
Gender:
ALL
Ages:
Between 6 months and 47 months
Trial Updated:
01/29/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Dravet Syndrome
Register for Updates
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
NCT05831176
Recruiting
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the eff... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/28/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis, Eosinophilic Gastrointestinal Disease
Register for Updates
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
01/27/2025
Locations: 279 Star Vision Consultants, Fort Worth, Texas
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Register for Updates
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
NCT05955261
Recruiting
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML * Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secon... Read More
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
01/27/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty
NCT05493709
Recruiting
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
01/24/2025
Locations: Cook Children's, Fort Worth, Texas
Conditions: Puberty; Precocious, Central
Register for Updates